



2017 Bayer Endowed Chair & Investigator Awarding Ceremony

2017 拜耳讲席教授奖 & 研究员奖 授奖仪式

2017-05-12 (09:00AM – 11:20AM)

Peking University
No.8 Ball Room, 2/F, Yingjie Communication Center
北京大学英杰交流中心 2 层第八会议室

AGENDA

- 09:00-09:05 Opening and Introduction
Dr. Xun Zhang
Alliance Manager, Innovation Center China, Drug Discovery, Bayer
- 09:05-09:15 Welcome Address and Opening Remarks
Prof. Hong Wu
Dean, School of Life Sciences, Peking University
- 09:15-09:25 The PKU-Bayer Partnership - an Outstanding and Versatile
Collaboration
Prof. Dr. Hanno Wild
Senior Vice President, Head of Candidate Generation & External
Innovation, Bayer
- 09:25-09:50 Awarding Session: Endowed Chair, Investigators, Postdoc
Dr. Hans Lindner
Vice President, Head of Global External Innovation & Alliances,
Bayer
- 09:50-10:15 What Can We Learn from a Vocal Primate on Auditory Perception?
Prof. Xiaoqin Wang
Professor, Departments of Biomedical Engineering, Neuroscience
and Otolaryngology, Johns Hopkins University
- 10:15-10:40 Oxygenation and Nitrogenation of Olefins and Alkynes
Prof. Ning Jiao
Professor, School of Pharmaceutical Sciences, Peking University
Health Science Center

10:40-11:05	A Glimpse into Cancer Metastasis Prof. Fan Bai Professor, School of Life Sciences, Peking University
11:05-11:10	Closing Remarks Dr. Tom Kinzel Head of Innovation Center China, Drug Discovery, Bayer
11:10-11:20	Group Photo

SPEAKER INTRODUCTION (In order of appearance)



Prof. Hong Wu
Peking University; Dean, School of Life Sciences

Dr. Hong Wu is Professor and Dean of School of Life Sciences, Peking University, and Senior Investigator of Peking-Tsinghua Center for Life Sciences. Before returning to China, Dr. Hong Wu was David Geffen Professor of Molecular and Medical Pharmacology and Director of Institute for Molecular Medicine, David Geffen School of Medicine at UCLA. Dr. Wu received her medical training from Beijing Medical College, China, and Ph.D. degree in Biological Chemistry from Harvard Medical School. After postdoctoral training as a Damon Runyon-Walter Winchell postdoctoral fellow at the Whitehead Institute for Biomedical Research, MIT, she joined UCLA as a faculty member. A major research focus of Dr. Wu's laboratory is to study the molecular mechanism of PTEN tumor suppressor controlled tumorigenesis. By generating tissue-specific PTEN deficient animal models, Dr. Wu's laboratory elucidated the important role of PTEN in regulating stem cell self-renewal, proliferation, and survival, as well as its roles in controlling the PI3K pathway. These models have been used for pre-clinical studies of new therapeutic agents and for identifying biomarkers for human cancers.



Prof. Dr. Hanno Wild

Bayer; Senior Vice President, Head of Candidate Generation & External Innovation, Drug Discovery


Prof. Dr. Hanno Wild is currently Head of Candidate Generation & External Innovation function of Drug Discovery, Bayer Pharmaceuticals, with major locations in Wuppertal and Berlin, Germany. In this role, he is responsible for the identification and optimization of low-molecular-weight drug candidates for all therapeutic research groups, for the chemistry of antibody-drug conjugates and antibody-thorium conjugates for cancer therapy, as well as for the generation and management of external partnerships and alliances. Prof. Wild, trained in chemistry, holds a Ph.D. as well as an honorary professorship of the University Bonn. After his studies of chemistry in Bonn and a postdoc fellowship (University of California, Irvine, USA, Prof. Larry Overman), Prof. Wild started his career with Bayer as a Medicinal Chemist in 1988. From 1994 to 1996 he was a delegate at the Bayer Pharma Research Center in West Haven, Connecticut, USA, focusing on cancer research including the project leading to the marketed product Nexavar. Soon after his return to the Wuppertal Research Center he assumed the position as section head at the Medicinal Chemistry Department of Bayer, responsible for the indication "Atherosclerosis" as well as for several collaborations in the field of compound acquisition and chem-/bioinformatics. From 2002 to 2006 he was Vice President and Head of the Medicinal Chemistry Department of Bayer HealthCare in Wuppertal, Germany and from 2006 to 2007, Prof. Wild served as Senior Vice President Discovery Europe, Bayer HealthCare before taking over his current role.



Dr. Hans Lindner

Bayer; Vice President, Head of Global External Innovation & Alliances, Drug Discovery

In this role, which he assumed in 2014, he is overseeing activities for collaborations and external innovation models for early drug discovery and development. Hans is a registered pharmacist with a doctorate degree in pharmaceutical technology from university of Kiel. He has had a number of different positions in Pharmaceutical Industry. He started 1994 as formulation scientist at Arzneimittelwerk Dresden GmbH, then joining Ferring Pharmaceuticals where he finally led pharmaceutical development in Copenhagen. In 2004 he took over pharmaceutical development at Schwarz Pharma, Germany. After merger with UCB S.A. he was directing late phase pharmaceutical product development. In 2008, he joined Bayer as head of global pharmaceutical development, later setting up a new unit dedicated to external work. Hans is member of the editorial board of the European Journal of Pharmaceutics and Biopharmaceutics, member of various professional associations and past vice president of the European Association Pharma Biotechnology (EAPB).



Prof. Xiaoqin Wang

**Johns Hopkins University; Departments of Biomedical Engineering, Neuroscience and Otolaryngology
Tsinghua University; Department of Biomedical Engineering**

Dr. Xiaoqin Wang received B.S. in electrical engineering from Sichuan University in 1984, M.S.E. in electrical engineering and computer science from University of Michigan in 1986, and Ph.D. in biomedical engineering from the Johns Hopkins University in 1991. He conducted postdoctoral research in somatosensory and auditory neuroscience at University of California, San Francisco (1991-1995). Dr. Wang has been a faculty member of Biomedical Engineering Department at the Johns Hopkins University School of Medicine since 1995. He has served as the director of Tsinghua-Johns Hopkins Joint Center for Biomedical Engineering Research since 2008 and was appointed Professor and Chair of the Department of Biomedical Engineering at Tsinghua University in 2010 (part-time). Dr. Wang received U.S. Presidential Early Career Award for Scientists and Engineers (PECASE) in 1999, Chang Jiang Scholar in 2007 and China's 1000 Talent Award in 2010.

Dr. Wang's research is in the areas of auditory neuroscience and neural engineering. His work has focused on the understanding of the structure and functions of the auditory cortex and the neural basis of vocal communication and music perception. His laboratory has developed a unique experimental model, a highly vocal New World primate - the common marmoset (*Callithrix jacchus*). Using this model system, Dr. Wang's lab has systematically studied neural coding properties of the auditory cortex in awake and behaving conditions, revealed specialized cortical representations of complex sound features such as pitch and harmonicity and discovered neural mechanisms involved in vocal feedback control and self-monitoring during speaking. Using newly developed cochlear implant and wireless neural recording techniques in freely roaming

marmosets, Dr. Wang's laboratory is currently studying neural mechanisms underlying cortical processing of vocal communication signals in both normal and hearing-impaired conditions.



Prof. Ning Jiao

Peking University Health Science Center; School of Pharmaceutical Sciences

Ning Jiao received his Ph.D. degree (2004) with Prof. Shengming Ma at Shanghai Institute of Organic Chemistry (SIOC). He then spent 2004-2006 as an Alexander von Humboldt Postdoctoral Fellow with Prof. Manfred T. Reetz at Max Planck Institute für Kohlenforschung. In 2007, he joined the faculty at Peking University as an associate professor, and was promoted to full professor in 2010. His current research efforts are focused on: 1) To develop synthetic methodologies through Single Electron Transfer (SET) and the application in bioactive compounds synthesis; 2) Aerobic oxidation, Oxygenation, Nitrogenation, and Halogenation reactions; 3) The first-row transition metal catalysis and the inert chemical bonds activation.



Prof. Fan Bai

Peking University; School of Life Sciences

Dr. Fan Bai received BSc (Physics) from Peking University in 2003 and DPhil (Biophysics) from University of Oxford in 2008. After three years postdoctoral training at University of Oxford and Osaka University, he returned to China in 2011 and lead his own research team. Dr. Fan Bai is pioneering the application of single cell sequencing in cancer metastasis study. In 2013, Dr. Bai and co-workers published the world's first whole genome sequencing of individual circulating tumor cells collected from cancer patients' peripheral blood (PNAS) and received broad media coverage. Especially, this work was featured in "Singled out for sequencing", the special yearly review published by Nature Methods. Recently, Dr. Bai investigated multiple tumor lesions in patients with Hepatocellular Carcinoma, revealing remarkable intra-tumor heterogeneity and the genetic feature of intra-liver metastases (Gastroenterology). Dr. Bai and his team aim to reveal the molecular and genetic mechanisms of cancer metastasis and explore the clinical value of sequencing circulating tumor cells for non-invasive cancer diagnosis, prognosis and therapy evaluation.




Dr. Tom Kinzel

Bayer; Head of Innovation Center China, Drug Discovery

Tom received his PhD in organic chemistry from the University of Göttingen in 2008 where he studied reaction mechanism and selectivities using a combined computational and experimental approach. He then moved to the Massachusetts Institute of Technology as postdoctoral fellow, working on Palladium-catalyzed cross-coupling reactions. Tom joined Bayer in 2011 and worked for three years as lab head in medicinal chemistry in Wuppertal. In 2014, he moved to Berlin and became the assistant of the head of the Drug Discovery organization. Since January 2016, Tom is the head of the Innovation Center China, which identifies opportunities, aligns, and manages research collaboration projects between Bayer Drug Discovery scientists and outstanding Chinese academic institutions as well as CROs. In 2001/2002, Tom spent one year in China, studying Chinese at Nanjing University and completing an internship in molecular biology at the Chinese Academy of Sciences in Shanghai.

2017 Bayer Endowed Chair Introduction



Prof. Xiaoqin Wang

**Johns Hopkins University; Departments of Biomedical Engineering, Neuroscience and Otolaryngology
Tsinghua University; Department of Biomedical Engineering**

Dr. Xiaoqin Wang received B.S. in electrical engineering from Sichuan University in 1984, M.S.E. in electrical engineering and computer science from University of Michigan in 1986, and Ph.D. in biomedical engineering from the Johns Hopkins University in 1991. He conducted postdoctoral research in somatosensory and auditory neuroscience at University of California, San Francisco (1991-1995). Dr. Wang has been a faculty member of Biomedical Engineering Department at the Johns Hopkins University School of Medicine since 1995. He has served as the director of Tsinghua-Johns Hopkins Joint Center for Biomedical Engineering Research since 2008 and was appointed Professor and Chair of the Department of Biomedical Engineering at Tsinghua University in 2010 (part-time). Dr. Wang received U.S. Presidential Early Career Award for Scientists and Engineers (PECASE) in 1999, Chang Jiang Scholar in 2007 and China's 1000 Talent Award in 2010.

Dr. Wang's research is in the areas of auditory neuroscience and neural engineering. His work has focused on the understanding of the structure and functions of the auditory cortex and the neural basis of vocal communication and

music perception. His laboratory has developed a unique experimental model, a highly vocal New World primate - the common marmoset (*Callithrix jacchus*). Using this model system, Dr. Wang's lab has systematically studied neural coding properties of the auditory cortex in awake and behaving conditions, revealed specialized cortical representations of complex sound features such as pitch and harmonicity and discovered neural mechanisms involved in vocal feedback control and self-monitoring during speaking. Using newly developed cochlear implant and wireless neural recording techniques in freely roaming marmosets, Dr. Wang's laboratory is currently studying neural mechanisms underlying cortical processing of vocal communication signals in both normal and hearing-impaired conditions.

2017 Bayer Investigator Awardee

Introduction (In alphabetical order)



Prof. Fan Bai

Peking University; School of Life Sciences

Dr. Fan Bai received BSc (Physics) from Peking University in 2003 and DPhil (Biophysics) from University of Oxford in 2008. After three years postdoctoral training at University of Oxford and Osaka University, he returned to China in 2011 and lead his own research team. Dr. Fan Bai is pioneering the application of single cell sequencing in cancer metastasis study. In 2013, Dr. Bai and co-workers published the world's first whole genome sequencing of individual circulating tumor cells collected from cancer patients' peripheral blood (PNAS) and received broad media coverage. Especially, this work was featured in "Singled out for sequencing", the special yearly review published by Nature Methods. Recently, Dr. Bai investigated multiple tumor lesions in patients with Hepatocellular Carcinoma, revealing remarkable intra-tumor heterogeneity and the genetic feature of intra-liver metastases (Gastroenterology). Dr. Bai and his team aim to reveal the molecular and genetic mechanisms of cancer metastasis and explore the clinical value of sequencing circulating tumor cells for non-invasive cancer diagnosis, prognosis and therapy evaluation.



Prof. Hao Huang

**Peking University Shenzhen Graduate School;
School of Chemical Biology and Biotechnology**

Hao Huang is currently a Principle Investigator in the School of Chemical Biology and Biotechnology at PKU Shenzhen Graduate School. He received his Ph.D from the University of Calgary, Canada. Before joining PKU, he worked at Astex Pharmaceuticals (Cambridge, UK) as a senior research scientist. In Shenzhen, his lab works on the anticancer drug discovery in the ubiquitin-proteasome system. The primary approaches used in his lab include Fragment Based Drug Discovery (FBDD) and structure based rational design. In the past, Dr. Huang discovered the working mechanism of the 1st E2 enzyme inhibitor CC0651 and this result provides new opportunities for E2 protein family inhibitor discovery. He is also a recipient of the Chinese 1000 Talents Plan-Young Professional.



Prof. Ning Jiao

**Peking University Health Science Center; School of
Pharmaceutical Sciences**

Ning Jiao received his Ph.D. degree (2004) with Prof. Shengming Ma at Shanghai Institute of Organic Chemistry (SIOC). He then spent 2004-2006 as an Alexander von Humboldt Postdoctoral Fellow with Prof. Manfred T. Reetz at Max Planck Institute für Kohlenforschung. In 2007, he joined the faculty at Peking University as an associate professor, and was promoted to full professor in 2010. His current research efforts are focused on: 1) To develop synthetic methodologies through Single Electron Transfer (SET) and the application in bioactive compounds synthesis; 2) Aerobic oxidation, Oxygenation, Nitrogenation, and Halogenation reactions; 3) The first-row transition metal catalysis and the inert chemical bonds activation.



Prof. Zigang Li

**Peking University Shenzhen Graduate School;
School of Chemical Biology and Biotechnology**

Prof. Li obtained his Bachelor from University of Science and Technology of China in 2001, and Master from Department of Chemistry, Tulane University in 2004, under the guidance of Prof. Chao-Jun Li.

In 2008, he received his Ph.D. from Department of Chemistry, University of Chicago, under the guidance of Prof. Chuan He. He did Post-doc training under the guidance of Prof. Gregory Verdine from 2009-2010 in Department of Chemistry and Chemical Biology from Harvard University. Prof. Li's research focus is developing novel methods to obtain peptides with enhanced biological functions.




Prof. Yujie Sun

Peking University; School of Life Sciences

Dr. Yujie Sun obtained his Bachelor from the University of Science and Technology of China, PhD degree from the University of Pittsburgh, and postdoctoral training at the University of Pennsylvania School of Medicine. In 2011, Dr. Sun joined the Biodynamic

Optical Imaging Center (BIOPIIC), School of Life Sciences, Peking University, as an assistant professor. At BIOPIIC, Dr. Sun has been developing advanced single molecule and super-resolution imaging techniques to study the structure-function relationship of chromatin and had more than 30 publications over the past 6 years. Dr. Sun has been serving as a board member of the National Committee of Biophysical Chemistry, Chinese Chemical Society, the National Committee of Single Molecule Biology, Chinese Biophysical Society, the National Committee of China Society of Image and Graphics, and associate director of the confocal microscopy division of China Society of Electron Microscopy. Dr. Sun has been awarded the Chinese Thousand Youth Talents Plan in 2011 and the Elsevier Scopus Young Scientist Award in 2012.



Prof. Fuchou Tang

Peking University; School of Life Sciences

Dr. Fuchou Tang is a principal investigator at BIOPIC, College of Life Sciences, Peking University. He joined BIOPIC of Peking University as a group leader in 2010. His lab focuses on studying gene regulation network in human early embryos as well as germline cells. His lab pioneered the single cell omics sequencing field and has systematically developed single cell functional genomics sequencing technologies, such as single cell polyA-independent RNA-seq (SUPER-seq), single cell DNA methylome sequencing (scRRBS), and single cell multiple omics sequencing (scTrio-seq). His lab has thoroughly analyzed the dynamics of gene expression network as well as epigenomic reprogramming in human early embryos and germline cells. His work has been cited for more than 4,000 times. He is an editorial board member for *Genome Biology*, *Science Bulletin*, and *Open Biology*. His work has been selected as top 10 scientific and technological progresses of China in the year of 2014 and top 10 scientific and technological progresses of China in the year of 2015.

